JP2731329B2 - Skin cosmetics - Google Patents

Skin cosmetics

Info

Publication number
JP2731329B2
JP2731329B2 JP32275992A JP32275992A JP2731329B2 JP 2731329 B2 JP2731329 B2 JP 2731329B2 JP 32275992 A JP32275992 A JP 32275992A JP 32275992 A JP32275992 A JP 32275992A JP 2731329 B2 JP2731329 B2 JP 2731329B2
Authority
JP
Japan
Prior art keywords
skin
effect
test
component
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP32275992A
Other languages
Japanese (ja)
Other versions
JPH06145038A (en
Inventor
朋宏 横田
正 松井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP32275992A priority Critical patent/JP2731329B2/en
Publication of JPH06145038A publication Critical patent/JPH06145038A/en
Application granted granted Critical
Publication of JP2731329B2 publication Critical patent/JP2731329B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業上の利用分野】本発明は、皮膚安全性に優れ、色
黒の皮膚を速やかに淡色化する効果及び角質層のターン
オーバー速度を亢進する効果を有し、使用感の優れた皮
膚安全性の高い皮膚化粧料に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is excellent in skin safety, has the effect of rapidly lightening dark-skinned skin and the effect of increasing the turnover speed of the stratum corneum, and has an excellent feeling in use. Highly skin cosmetics.

【0002】[0002]

【従来の技術及び発明が解決しようとする課題】紫外線
により皮膚は炎症(紅斑)を起こし種々の因子が放出さ
れメラノサイトを刺激する。これにより色調は変化し黒
化する。この黒化は、メラノサイトにおいて産生され表
皮細胞に受け渡されるメラニンの過剰生産が原因であ
り、メラニンはチロシンが酸化されて産生される。
2. Description of the Related Art Ultraviolet rays cause inflammation (erythema) on the skin and release various factors to stimulate melanocytes. As a result, the color tone changes and blackens. This darkening is due to overproduction of melanin, which is produced in melanocytes and passed to epidermal cells, and is produced by oxidation of tyrosine.

【0003】従来より、皮膚の黒化やしみ、そばかすを
防ぎ本来の白い肌を保つために、この酸化を防止するビ
タミンCの誘導体、ハイドロキノンモノベンジルエーテ
ル、過酸化水素等を配合した皮膚化粧料が提案されてい
る。
[0003] Conventionally, skin cosmetics containing a derivative of vitamin C, hydroquinone monobenzyl ether, hydrogen peroxide, etc., for preventing oxidation, in order to prevent darkening, spots and freckles on the skin and to maintain the original white skin. Has been proposed.

【0004】しかし、これらの皮膚化粧料中にビタミン
C誘導体を配合すると保存安定性が不充分であるか、美
白効果が充分に認められないことが多い。美白化粧料中
にハイドロキノンモノベンジルエーテル等を配合する
と、色黒の肌を淡色化する効果はあるが、皮膚の安全性
にも問題がある等の欠点がある。この様に、美白効果に
優れ、皮膚安全性が高い皮膚化粧料を得ることは困難を
極めている。
[0004] However, when a vitamin C derivative is incorporated into these skin cosmetics, the storage stability is often insufficient or the whitening effect is not sufficiently recognized. When hydroquinone monobenzyl ether or the like is blended in a whitening cosmetic, it has the effect of lightening dark-skinned skin, but has drawbacks such as a problem in skin safety. As described above, it is extremely difficult to obtain a skin cosmetic having an excellent whitening effect and high skin safety.

【0005】また、カンゾウの疎水性成分であるグラブ
リジンを単独で配合した場合、抗菌作用、抗酸化作用、
抗う触作用、抗プラスミン、メラニン生成抑制作用を有
することが確認されている。しかし、美白効果は優れて
いるものの使用感は十分に満足するものではなかった。
[0005] In addition, when glabridine, which is a hydrophobic component of licorice, is blended alone, the antibacterial action, antioxidant action,
It has been confirmed that it has an antinociceptive effect, an antiplasmin and an inhibitory effect on melanin production. However, although the whitening effect was excellent, the feeling of use was not sufficiently satisfactory.

【0006】また、γ−アミノ酪酸及びその誘導体は皮
膚の抹消血管拡張作用有することが知られている物質で
ある。これらを単独で配合した場合、ある程度の皮膚の
代謝促進効果は得られるものの、その使用感は満足する
ものではなかった。
[0006] Also, γ-aminobutyric acid and its derivatives are substances known to have a peripheral vasodilatory effect on the skin. When these are used alone, a certain degree of skin metabolism promoting effect can be obtained, but the feeling of use has not been satisfactory.

【0007】[0007]

【課題を解決するための手段】本発明者らは、このよう
な状況に鑑み、従来技術の難点を改良せんとして鋭意研
究を重ねた結果、グラブリジンとγ−アミノ酪酸及びそ
の誘導体を配合したものが、相乗作用によって美白効果
に顕著に優れ、角質層のターンオーバー速度を亢進する
効果を有し、使用感の優れた皮膚安全性が高い皮膚化粧
料となることを見いだし、本発明の完成に至った。
Means for Solving the Problems In view of such circumstances, the present inventors have conducted intensive studies to improve the disadvantages of the prior art, and as a result, a compound obtained by combining glabridine with γ-aminobutyric acid and a derivative thereof. However, it has been found that the synergistic effect is remarkably excellent in whitening effect, has an effect of enhancing the turnover speed of the stratum corneum, and is a skin cosmetic with high feeling of use and high skin safety, and has been completed in the present invention. Reached.

【0008】即ち、本発明は、美白効果に優れ、角質層
のターンオーバー速度を亢進する効果を有し、皮膚安全
性が高く、使用感の優れた皮膚化粧料を提供することを
目的とするものである。
[0008] That is, an object of the present invention is to provide a skin cosmetic composition which is excellent in whitening effect, has an effect of increasing the turnover speed of the stratum corneum, has high skin safety and is excellent in use feeling. Things.

【0009】上記の目的を達成するために、本発明の皮
膚化粧料は次のような構成をとる。即ち、本発明はグラ
ブリジンとγ−アミノ酪酸及びその誘導体の少なくとも
一つとを含有することを特徴とする皮膚化粧料である。
In order to achieve the above object, the skin cosmetic of the present invention has the following constitution. That is, the present invention is a skin cosmetic comprising glabridine and at least one of γ-aminobutyric acid and a derivative thereof.

【0010】本発明の皮膚化粧料に用いられるグラブリ
ジンは、天然には、甘草の一種であるGlycyrrhiza glab
a Linne var.(通称ロシア・アフガン・トルコカンゾ
ウ)に微量含まれている。グラブリジンの製造法として
は、甘草の根または、その水抽出残渣(例えばグリチル
リチンを抽出した残渣)を有機溶媒で抽出する。抽出溶
媒としては、メタノール、エタノール等の低級脂肪族ア
ルコール、アセトン等の低級脂肪族ケトン、ジオキサ
ン、エチルエーテル等のエーテル類、塩化メチレン等の
ハロゲン化炭化水素類、酢酸エチル等のエステル類、ヘ
キサン等の炭化水素類の有機溶媒の2種以上の混合物を
使用することができる。抽出する甘草は、約5〜15倍
量の上記溶媒に浸漬し、常温で静置するか還流下に加熱
する。抽出液から溶媒を留去して得られる抽出物は、通
常5〜10%程度のグラブリジンを含有している。精製
は、例えば順相シリカゲルカラムクロマトグラフィー及
び逆相シリカゲルカラムクロマトグラフィーにより処理
した後アセトンから結晶化する方法により、比較的容易
にグラブリジンの純品を得ることができる。精製は他に
も合成吸着体によるカラムクロマトグラフィー等の任意
の有機化合物精製手段を採用して行なうことができる。
Glabridin used in the skin cosmetic composition of the present invention is naturally a kind of licorice, Glycyrrhiza glab
a A trace amount is contained in Linne var. (commonly known as Russia, Afghanistan and Turkey licorice). As a method for producing grabradine, licorice root or a water-extraction residue thereof (for example, a residue obtained by extracting glycyrrhizin) is extracted with an organic solvent. Examples of the extraction solvent include lower aliphatic alcohols such as methanol and ethanol, lower aliphatic ketones such as acetone, ethers such as dioxane and ethyl ether, halogenated hydrocarbons such as methylene chloride, esters such as ethyl acetate, and hexane. And mixtures of two or more organic solvents such as hydrocarbons. The licorice to be extracted is immersed in about 5 to 15 times the amount of the above solvent, and left standing at room temperature or heated under reflux. The extract obtained by distilling off the solvent from the extract usually contains about 5 to 10% of glabridine. For purification, a pure glabridine product can be obtained relatively easily by, for example, a method of treating with normal-phase silica gel column chromatography and reverse-phase silica gel column chromatography and then crystallization from acetone. Purification can be performed by any other means for purifying organic compounds such as column chromatography using a synthetic adsorbent.

【0011】本発明の皮膚化粧料に用いられるγ−アミ
ノ酪酸及びその誘導体は公知化合物であり、γ−アミノ
酪酸(以下GABAと略記)及びその誘導体としてN−
メチル−γ−アミノ酪酸(以下MGAと略記)、N−ジ
メチル−γ−アミノ酪酸(以下DMGAと略記)、γ−
アミノ酪酸オレイルエステル(以下GABAOEと略
記)等のN−アルキル体及びエステル類がある。
Γ-Aminobutyric acid and its derivatives used in the skin cosmetic of the present invention are known compounds, and γ-aminobutyric acid (hereinafter abbreviated as GABA) and N-
Methyl-γ-aminobutyric acid (hereinafter abbreviated as MGA), N-dimethyl-γ-aminobutyric acid (hereinafter abbreviated as DMGA), γ-
There are N-alkyl compounds and esters such as oleyl aminobutyrate (hereinafter abbreviated as GABAOE).

【0012】グラブリジンの本発明の皮膚化粧料中への
配合量は、総量を基準として、好ましくは、0.001
〜3.0重量%(以下wt%とする)である。
The amount of glabridine in the skin cosmetic composition of the present invention is preferably 0.001% based on the total amount.
To 3.0% by weight (hereinafter referred to as wt%).

【0013】γ−アミノ酪酸の本発明の皮膚化粧料中へ
の配合量は、乾燥固形物量で、総量を基準として、好ま
しくは、0.01〜5.0wt%である。
The amount of γ-aminobutyric acid in the skin cosmetic composition of the present invention is preferably 0.01 to 5.0% by weight, based on the total amount of dry solids.

【0014】グラブリジンの配合量が0.001w%未
満で、γ−アミノ酪酸及びその誘導体が0.01w%で
は本発明の目的とする効果に充分ではなく、グラブリジ
ンの配合量が3.0w%、γ−アミノ酪酸及びその誘導
体が5.0w%をそれぞれ超えても、その増加分に見合
った効果の向上は望めず、使用時の感触が悪くなり易
く、個々の剤型を保持し難くなる。
If the amount of glabridine is less than 0.001% by weight and the amount of γ-aminobutyric acid and its derivative is 0.01% by weight, the effect of the present invention is not sufficient, and the amount of glabridine is 3.0% by weight. Even if γ-aminobutyric acid and its derivative exceed 5.0% by weight, the effect corresponding to the increase cannot be expected, and the feeling at the time of use tends to deteriorate, and it becomes difficult to hold individual dosage forms.

【0015】本発明の皮膚化粧料は、常法に従って、ロ
ーション類、乳液類、クリーム類、パック類等の剤型に
することが可能である。
The skin cosmetic composition of the present invention can be made into a dosage form such as lotions, emulsions, creams, packs, etc. according to a conventional method.

【0016】尚、本発明の皮膚化粧料には、色素、香
料、防腐剤、界面活性剤、顔料等を本発明の目的を達成
する範囲で適宜配合することができる。
The skin cosmetics of the present invention can be appropriately blended with pigments, fragrances, preservatives, surfactants, pigments and the like within a range that achieves the object of the present invention.

【0017】[0017]

【実施例】以下、実施例及び比較例に基づいて本発明を
詳細に説明する。
The present invention will be described below in detail based on examples and comparative examples.

【0018】実施例に記載の(1)チロシナーゼ活性阻
害試験(2)皮膚色明度回復試験(3)美白実用試験
(4)角質層のターンオーバー速度測定試験(5)光パ
ッチ試験の各試験法は次の通りである。
(1) Tyrosinase activity inhibition test (2) Skin color lightness recovery test (3) Whitening practical test (4) Stratum corneum turnover speed measurement test (5) Optical patch test Is as follows.

【0019】(1)チロシナーゼ活性阻害試験 マックルベイン緩衝液(pH6.8)1mlに0.3m
g/ml濃度のチロシン溶液に各濃度の試料溶液を加
え、37℃にて10分間の予備保温を行う。これに1m
g/ml濃度のチロシナーゼ(シグマ社製)0.1ml
を加え37℃にて15分間加温した後、分光光度計を用
いて、波長475nmにて吸光度(A)を測定した。一
方、チロシナーゼの代わりに緩衝液0.1mlを加えた
ものの吸光度(B)、試料溶液の代わりに緩衝液0.1
ml加えたものの吸光度(C)、更に試料溶液とチロシ
ナーゼの代わりに緩衝液0.2ml加えたものの吸光度
(D)をそれぞれ測定して、下式に従い阻害率(%)を
算出した。
(1) Tyrosinase activity inhibition test 0.3 m per 1 ml of McClubine buffer (pH 6.8)
The sample solution of each concentration is added to the tyrosine solution having a concentration of g / ml, and preliminarily kept at 37 ° C. for 10 minutes. 1m to this
0.1 ml of tyrosinase (manufactured by Sigma) at a concentration of g / ml
After heating at 37 ° C. for 15 minutes, the absorbance (A) was measured at a wavelength of 475 nm using a spectrophotometer. On the other hand, the absorbance (B) obtained by adding 0.1 ml of buffer solution instead of tyrosinase,
The absorbance (C) of the solution to which the solution had been added and the absorbance (D) of the solution to which 0.2 ml of the buffer had been added instead of the sample solution and tyrosinase were measured, and the inhibition rate (%) was calculated according to the following formula.

【0020】 阻害率(%)={1−(A−B)/(C−D)} ×100Inhibition rate (%) = {1- (AB) / (CD)} × 100

【0021】(2)皮膚色明度回復試験 被試験者20名の上腕内側部皮膚にUVA、UVB領域
の紫外線の最小紅斑量を3日間連続照射して照射終了
後、試料塗布部とベース塗布部皮膚の基準明度(V0
値、V0 ´値)を測定した。引き続いて、1日3回ずつ
4週間連続で塗布し、照射開始1、2、4週間後の試料
塗布部とベース塗布部皮膚の皮膚明度(Vn値、Vn ´
値)を測定して、下記の判定基準により皮膚色の回復評
価を行った。
(2) Skin lightness recovery test The skin of the upper inner arm of the 20 test subjects was continuously irradiated with the minimum amount of UVA and UVB erythema in the UVA and UVB regions for 3 days. After the irradiation was completed, the sample application section and the base application section were applied. Reference lightness of skin (V0
(V0 'value) was measured. Subsequently, the composition was applied three times a day for four consecutive weeks, and the skin lightness (Vn value, Vn ′) of the sample-applied part and the base-applied part at 1, 2, and 4 weeks after the start of irradiation
Was measured, and the skin color was evaluated for recovery according to the following criteria.

【0022】尚、皮膚の明度(マンセル表示系V値)
は、高速分光色彩計で測定して得られX、Y、Z値より
算出した。又、評価は被試験者20名の4週間後の評価
点の平均値で示した。
The brightness of the skin (V value of Munsell display system)
Was calculated from X, Y, and Z values obtained by measuring with a high-speed spectral colorimeter. The evaluation was shown as an average of the evaluation points of the 20 test subjects after 4 weeks.

【0023】[0023]

【表1】 [Table 1]

【0024】(3)美白実用試験 夏期の太陽光に3時間(1日1.5時間で2日間)曝さ
れた被試験者20名の前腕屈側部皮膚を対象として、左
前腕屈側部皮膚には太陽光に曝された日より、試料を、
右前腕屈側部皮膚には太陽光に曝された日よりベースを
朝夕1回ずつ13週連続塗布した。
(3) Practical skin whitening test The left forearm flexing side skin of 20 test subject's forearm flexing side skin exposed to sunlight in summer for 3 hours (1.5 hours a day for 2 days). From the day of sun exposure to the skin,
The base was applied to the right forearm flexion side skin once a day in the morning and evening for 13 weeks from the day of exposure to sunlight.

【0025】尚、評価はベース塗布部より試料塗布部の
効果を確認された被験者の人数で示した。
The evaluation was made based on the number of subjects who confirmed the effect of the sample application section from the base application section.

【0026】(4)角質層のターンオーバー速度測定試
験 被験者20名の前腕屈側部皮膚2カ所に1.5MEDの
UVBを1回照射し、3日後に蛍光色素であるダンシル
クロライドを白色ワセリン中に5%wt配合した軟膏を
照射部皮膚に24時間閉塞塗布し、角質層にダンシルク
ロライドを浸透させる。その後、同部位に1日3回
(朝、昼、入浴後)試料とベースを塗布し、毎日ダンシ
ルクロライドの蛍光をしらべ、その蛍光が消滅するまで
の日数を調べ皮膚角質層のターンオーバー速度とした。
尚、通常の皮膚角質層のターンオーバー速度は14〜1
6日である。
(4) Test for measuring the turnover speed of the stratum corneum Twenty subjects were irradiated once with 1.5 MED UVB at two sites on the flexor side of the forearm. Three days later, dansyl chloride, a fluorescent dye, was placed in white petrolatum. Ointment mixed with 5% by weight is applied to the irradiated skin for 24 hours, and dansyl chloride is penetrated into the stratum corneum. Thereafter, a sample and a base are applied to the same site three times a day (morning, afternoon, after bathing), and the fluorescence of dansyl chloride is examined every day. The number of days until the fluorescence disappears is determined, and the turnover speed of the stratum corneum of the skin is determined. did.
In addition, the normal skin stratum corneum turnover speed is 14 to 1
Six days.

【0027】(5)光パッチ試験 被験者25名の前腕屈側部皮膚に試料0.05gを塗布
した直径1.0cmのパッチ板を用いて24時間クロー
ズドパッチを行った後、夏期の太陽光を6時間(1日3
時間で2日間)照射した。
(5) Optical Patch Test Closed patching was performed for 24 hours using a 1.0 cm diameter patch plate on which 0.05 g of a sample was applied to the skin of the flexed side of the forearm of 25 subjects. 6 hours (3 days a day)
Irradiation for 2 days).

【0028】評価は、下記の判定基準に従い、被験者2
5名の皮膚の状態を評価判定した。判定結果は、照射2
4時間後に、(±)以上の人数で示した。
The evaluation was performed according to the following criteria.
The skin condition of five persons was evaluated and evaluated. The judgment result is irradiation 2
Four hours later, the number was indicated by (±) or more.

【0029】[0029]

【表2】 [Table 2]

【0030】(6)官能試験 被験者20名が試料を10日間連用した後の試料の特性
を評価した。
(6) Sensory Test Twenty test subjects evaluated the characteristics of the sample after continuously using the sample for 10 days.

【0031】評価は湿潤性、親和性等のアンケート項目
に対し、「皮膚に潤いが生じた」、「皮膚への親和性が
良い」、「皮膚のつやが改善された」と回答した人数で
示した。
The evaluation was based on the questionnaire items such as wettability and affinity, and the number of respondents who answered "moistened skin", "good affinity for skin" and "improved skin luster". Indicated.

【0032】実施例1〜3、比較例1〜4 二相型ロー
ション 表3の原料組成において、表3に記載の如く有効成分を
配合して、二相型ローションを調製し、前記の諸試験を
実施した。
Examples 1 to 3 and Comparative Examples 1 to 4 Two-Phase Lotion In the raw material composition shown in Table 3, active ingredients were blended as shown in Table 3 to prepare a two-phase lotion. Was carried out.

【0033】[0033]

【表3】 [Table 3]

【0034】[0034]

【表4】 [Table 4]

【0035】(1)調製法 表3に記載のB成分をA成分中に、C成分をD成分中に
均一に溶解した後、A成分とD成分を均一に混合攪拌分
散し次いで容器に充填する。使用時には内容物を均一に
振盪分散して使用する。
(1) Preparation Method After dissolving the B component and the C component uniformly in the A component and the D component described in Table 3, the A component and the D component are uniformly mixed, stirred and dispersed, and then filled in a container. I do. When used, the contents are shaken and dispersed uniformly.

【0036】(2)特性 諸試験を実施した結果を表4に記載した。表4に示す如
く、比較例1は諸試験において良好な結果は示さなかっ
た。
(2) Characteristics Table 4 shows the results of various tests. As shown in Table 4, Comparative Example 1 did not show good results in various tests.

【0037】実施例1〜3の本発明の皮膚化粧料は諸試
験の総てにおいて明らかに良好な結果を示し、ヒト皮膚
での諸試験において皮膚刺激は生じなかった。
The skin cosmetic compositions of the present invention of Examples 1 to 3 showed clearly good results in all tests, and no skin irritation occurred in tests on human skin.

【0038】実施例4〜7、比較例5〜8 スキンクリ
ーム 表5の原料組成において、表6に記載の如く有効成分を
配合して、スキンクリームを調製し、前記諸試験を実施
した。
Examples 4 to 7, Comparative Examples 5 to 8 Skin Cream In the raw material composition shown in Table 5, active ingredients were blended as shown in Table 6 to prepare a skin cream, and the above-mentioned tests were carried out.

【0039】[0039]

【表5】 [Table 5]

【0040】[0040]

【表6】 [Table 6]

【0041】(1)調製法 表5に記載のB成分をA成分に混合し、A成分とD成分
をそれぞれ均一に加熱溶解して温度を80℃にする。次
いで、A成分中にD成分を注入攪拌混合した後、攪拌し
ながら冷却し、約50℃にてC成分を投入し30℃まで
冷却する。
(1) Preparation method The B component shown in Table 5 is mixed with the A component, and the A component and the D component are each uniformly heated and dissolved to bring the temperature to 80 ° C. Next, the component D is injected into the component A, mixed with stirring, cooled while stirring, and the component C is introduced at about 50 ° C. and cooled to 30 ° C.

【0042】諸試験を実施した結果を表6に示した。表
6に示す如く、実施例4〜6は、諸試験の総てにおいて
明らかに良好な結果を示し、ヒト皮膚での諸試験におい
て良好な結果を示し、ヒト皮膚での諸試験において皮膚
刺激は生じなかった。
Table 6 shows the results of the tests. As shown in Table 6, Examples 4 to 6 showed clearly good results in all tests, good results in tests on human skin, and skin irritation in tests on human skin. Did not occur.

【0043】以上記載の如く、本発明は美白効果と角質
層のターンオーバー速度亢進効果に優れ、皮膚刺激が無
く、使用感の優れた有用な皮膚化粧料を提供することは
明らかである。
As described above, it is apparent that the present invention provides a useful skin cosmetic which has an excellent whitening effect and an effect of enhancing the turnover speed of the stratum corneum, has no skin irritation, and has an excellent feeling upon use.

Claims (1)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 γ−アミノ酪酸及びその誘導体の少なく
とも一つとグラブリジンとを含有することを特徴とする
皮膚化粧料。
1. A skin cosmetic comprising at least one of γ-aminobutyric acid and its derivatives and glabridine.
JP32275992A 1992-11-05 1992-11-05 Skin cosmetics Expired - Fee Related JP2731329B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP32275992A JP2731329B2 (en) 1992-11-05 1992-11-05 Skin cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32275992A JP2731329B2 (en) 1992-11-05 1992-11-05 Skin cosmetics

Publications (2)

Publication Number Publication Date
JPH06145038A JPH06145038A (en) 1994-05-24
JP2731329B2 true JP2731329B2 (en) 1998-03-25

Family

ID=18147329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP32275992A Expired - Fee Related JP2731329B2 (en) 1992-11-05 1992-11-05 Skin cosmetics

Country Status (1)

Country Link
JP (1) JP2731329B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958976A (en) * 1997-09-19 1999-09-28 E-L Management Corp. Composition and method for reducing stinging in skin
JP2004352629A (en) * 2003-05-28 2004-12-16 Kuraray Co Ltd External preparation for skin
FR2909280B1 (en) * 2006-11-30 2015-04-17 Marcel Georges Cohen USE OF GAMMA-AMINOBUTYRIC ACID AS DEPIGMENTING AGENT
KR20100138918A (en) 2008-03-11 2010-12-31 가부시키가이샤 시세이도 Skin whitening method and screening method for factors for skin wrinkle formation suppression and/or removal

Also Published As

Publication number Publication date
JPH06145038A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
JP6081633B2 (en) Kouzo extract
US20110182835A1 (en) Topical Cosmetic Skin Lightening Compositions and Methods of use Thereof
KR101078888B1 (en) A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof
EP0486595B1 (en) Use of a coleus extract for skin pigmentation
JP3195684B2 (en) Skin cosmetics
JP2986262B2 (en) Whitening cosmetics
JP2731329B2 (en) Skin cosmetics
KR100530669B1 (en) Cosmetic Compositions Comprising Lactate and Glycyrrhiza Uralensis Extracts for Skin Whitening
CA2706992C (en) Topical cosmetic skin lightening compositions and methods of use thereof
JP2702860B2 (en) Skin cosmetics
KR100681700B1 (en) Cosmetic composition for skin whitening comprising senkyunolide a and gluconic acid as active ingredients
JP3197651B2 (en) Skin cosmetics
JP2000256175A (en) Cosmetic composition
KR20030043471A (en) Cosmetic Compositions Comprising Vitamin C or Derivatives thereof Areca catechu L extract for Preventing Skin Aging
EP2198847A2 (en) Compositions comprising self-tanning agents and plant extracts
JP2012509257A (en) Topical whitening cosmetic composition and method of use
JP2942409B2 (en) Whitening cosmetics
JPH0971520A (en) Skin cosmetic
JP3071293B2 (en) Whitening cosmetics
EP2198848A2 (en) Compositions comprising self-tanning agents and sugar amines
JPH06206812A (en) Skin cosmetic
JP2000290131A (en) Bleaching preparation
JPH0710738A (en) Beautifying cosmetic
KR20010057429A (en) Skin care composition containing Ursolic acid
JP3649889B2 (en) Whitening cosmetics

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 12

Free format text: PAYMENT UNTIL: 20091219

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 13

Free format text: PAYMENT UNTIL: 20101219

FPAY Renewal fee payment (prs date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101219

Year of fee payment: 13

FPAY Renewal fee payment (prs date is renewal date of database)

Year of fee payment: 14

Free format text: PAYMENT UNTIL: 20111219

LAPS Cancellation because of no payment of annual fees